I

Invivyd Tech Stack

Antibody therapeutics platform with FDA-authorized monoclonal antibody for viral infections

Biotechnology Research New Haven, Connecticut 51–200 employees Founded 2020 Public Company

Invivyd is a public biotech company (Nasdaq: IVVD) developing antibody-based therapeutics designed to outperform the human immune response against viral pathogens. The company achieved FDA emergency use authorization for a monoclonal antibody candidate in March 2024. Hiring is accelerating across sales (40 open roles) and healthcare teams (14), with a leadership mix skewed toward directors and senior individual contributors — a pattern consistent with a company scaling commercial and clinical operations post-authorization.

Tech Stack 17 technologies

Core StackAzure AD Intune NetSuite SAP SAS Canva Adobe Illustrator Freshservice Windows macOS Microsoft 365 JAMF Conga Biacore Veeva R Photoshop

What Invivyd Is Building

◆Challenges

Patient access barriers
Complex reimbursement issues
Prior authorization denials
Resolving reimbursement denials
Cost efficiency in procurement
Ensuring compliance with healthcare regulations
Meeting needs of key partners
Regulatory changes impacting reimbursement
Optimizing medical crm
Privacy incident management

▲Active Projects

Optimizing medical crm
Market access organization
New product launch
Developing sops for field medical activities
Training healthcare professionals on reimbursement process
Community engagement webinars
Speaker bureau management
Strategic territory business plan
Hcp and patient congress engagements
Building foundation of field medical organization

Hiring Activity

Accelerating90 roles · 50 in 30d

Department

Sales

40

Healthcare

14

Marketing

11

Legal

4

Ops

4

Compliance

2

Data

2

Manufacturing

2

Seniority

Senior

35

Director

34

Manager

11

Junior

5

Mid

2

VP

1

Notable leadership hires: Medical Director, Sales Director, Medical Field Director, Regional Sales Director, National Accounts Director

Company intelligence

Find more companies like Invivyd by tech stack, pain points and active projects

Get started free

About Invivyd

Invivyd uses a proprietary antibody engineering platform to create monoclonal antibodies with improved potency and resistance to viral evolution. The company targets immunocompromised and viral-infection patient populations. Founded in 2020 and headquartered in New Haven, Connecticut, Invivyd operates with 51–200 employees and employs a technology stack spanning Veeva (life sciences data management), NetSuite (ERP), SAP, and specialized lab instrumentation (Biacore) alongside standard enterprise tools (Azure AD, Microsoft 365, Intune). Active projects center on field medical infrastructure, market access, reimbursement workflows, and healthcare professional training — functions typical of a therapeutic company preparing for or managing early commercialization.

HeadquartersNew Haven, Connecticut

Company Size51–200 employees

Founded2020

Hiring MarketsUnited States, India, Canada, Peru

Frequently Asked Questions

What is Invivyd's lead product?

Invivyd's lead candidate is a monoclonal antibody that received FDA emergency use authorization in March 2024. The company develops antibodies designed to be more potent and resistant to virus evolution than naturally occurring immune responses.

What software does Invivyd use for clinical data?

Invivyd's stack includes Veeva (life sciences data management), NetSuite (ERP), SAP, and SAS for analytics. Lab-specific tools include Biacore for protein interaction analysis.